Text Size
18 studies found for:    "Neurofibromatosis type 2"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"Neurofibromatosis type 2"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Neurofibromatosis 2;   Vestibular Schwannoma
Intervention: Drug: Lapatinib
2 Active, not recruiting Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Conditions: Acoustic Schwannoma;   Neurofibromatosis Type 2
Interventions: Biological: bevacizumab;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
3 Recruiting Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Conditions: Neurofibromatosis Type 2;   Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus
4 Not yet recruiting Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
5 Active, not recruiting Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Condition: Neurofibromatosis 2
Intervention: Drug: RAD001
6 Active, not recruiting Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
7 Suspended PTC299 for Treatment of Neurofibromatosis Type 2
Condition: Neurofibromatosis 2
Intervention: Drug: PTC299
8 Completed An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
Condition: Neurofibromatosis 2
Intervention: Device: Penetrating auditory brainstem implant
9 Recruiting Concentration and Activity of Lapatinib in Vestibular Schwannomas
Conditions: Vestibular Schwannoma;   NF2;   Neurofibromatosis 2;   Acoustic Neuroma;   Auditory Tumor
Intervention: Drug: lapatinib
10 Recruiting Natural History Study of Patients With Neurofibromatosis Type 2
Conditions: Spinal Cord Disease;   Intracranial Central Nervous System Disorder;   Neurologic Disorders;   Brain Neoplasms
Intervention:
11 Recruiting Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Conditions: Acoustic Schwannoma;   Adult Anaplastic Meningioma;   Adult Ependymoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Meningeal Hemangiopericytoma;   Adult Papillary Meningioma;   Neurofibromatosis Type 1;   Neurofibromatosis Type 2;   Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
12 Unknown † NF2 Natural History Consortium
Conditions: Schwannoma, Vestibular;   Neurofibromatosis 2;   Meningioma
Intervention:
13 Completed Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
Condition: Neurofibromatosis 2
Intervention: Device: Multichannel Auditory Brain Stem Implant
14 Recruiting Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Conditions: Neoplasms;   Nervous System Disease;   Vestibular Disease
Intervention:
15 Completed Analysis of NF2 Mutations in Radiation-Related Neural Tumors
Condition: Neural Tumors
Intervention:
16 Completed Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: everolimus
17 Not yet recruiting Feasibility Study of Auditory Brainstem Implant in Young Children
Conditions: Bilateral Cochlear Aplasia;   Bilateral Cochlear Nerve Deficiency;   Bilateral Cochlear Ossification Secondary to Meningitis
Intervention: Device: Auditory brainstem implant
18 Active, not recruiting Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Conditions: CNS Cancer;   Meningioma;   Intracranial Hemangiopericytoma;   Hemangioblastoma;   Neurofibromatosis
Intervention: Drug: Sunitinib
To Top

† Indicates status has not been verified in more than two years